Opioid Use Disorder: Pharmacotherapy

$45.00 | CE Hours:9.00 | Intermediate

CE Course Description

The United States is experiencing an opioid addiction epidemic.  This CE course describes general principles of opioid use disorder (OUD) pharmacotherapy and discusses medication formulations, indications, and dosing for the three FDA-approved medications used to treat OUD - methadone, naltrexone, and buprenorphine.  Patient management and monitoring in outpatient settings other than opioid treatment programs as well as medical management of patients with OUD in hospital settings is also discussed.

Author: Substance Abuse and Mental Health Services Administration.  Medications for Opioid Use Disorder.  Treatment Improvement Protocol (TIP) Series 63.  HHS Publication No. (SMA) 18-5063.  Rockville, MD: Substance Abuse and Mental Health Services Administration, 2018.

Retrieved from:  https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Executive-Summary/SMA18-5063EXSUMM

CE Course Objectives

1.  Differentiate between mu-opioid receptor full agonists, partial agonists, and antagonist.

2.  Give five indications that a patient is suitable for home induction.

3.  Explain why oral naltrexone is not widely used to treat opioid use disorder.

4.  Judge which OUD medication can be used during pregnancy.

5.  Consider three indications that medically supervised withdrawal using buprenorphine or methadone is appropriate for patients.

6.  Weigh three contraindications to receiving XR-NTX.

CE Outline with Main Points

1.  Overview of Pharmacotherapy for Opioid Use Disorder

a.  Introduction to Medications That Address OUD

b.  Principles of OUD Pharmacotherapy

c.  Overview of Medication Indications and Dosing

2.  Methadone

a.  Formulations

b.  Pharmacology

c.  Bioavailability

d.  Dosing Considerations

e.  Contraindications

f.  Initiating Methadone Treatment

g.  Duration of Methadone Treatment

h.  Methadone Dosing Summary

i.  Enhancing Access to OUD Medication in OTPs

3.  Naltrexone

a.  Formulations

b.  Pharmacology

c.  Dosing Considerations

d.  Naltrexone Dosing Summary

4.  Buprenorphine

a.  Formulations

b.  Pharmacology

c.  Bioavailability

d.  Dosing Considerations

e.  Initiating Buprenorphine Treatment

f.  Duration of Buprenorphine Treatment

5.  Medical Management Strategies for Patients Taking OUD Medications in Office-Based Settings

a.  Patient Selection

b.  Patient Management and Treatment Monitoring

c.  Administrative Considerations

d.  Emergency Protocols and Patient Safety Measures

e.  Recommendations for Staff Member Training

6.  Medical Management of Patients Taking OUD Medications in Hospital Settings

a.  Hospital Settings

b.  Hospitalized or ED Patients Taking Medication for OUD

c.  Hospitalized or ED Patients Not Taking Medication for OUD

d.  Medical Management Plan



Social Work Approval

Social Work CE Credit for this course is offered with the following approvals. Many state boards of social work will accept the approvals listed. Provider Approvals by state and license type can be found here.

  • Quantum Units Education is approved by the California Association of Marriage and Family Therapists, CAMFT Provider #89970, to sponsor continuing education for LMFTs, LCSWs, LPCCs, and/or LEP. Quantum Units Education maintains responsibility for this program/course and its content.
  • Florida board for Social Workers CE Provider #50-8650 (Quantum 'immediately' reports CE Credits to Florida licensees) 
  • Illinois Department of Professional Regulation, License No. 159.001261 approved CE Sponsor
  • Ohio CSWMFTB #RCST091701 approved CE Provider
  • Texas Board of SWE #5070 approved CE Provider
  • ACE credit is offered for this course for social workers (followed by ACE approval statement that is currently on every ACE course page) Quantum Units Education, #1289, is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved as ACE providers. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. Quantum Units Education maintains responsibility for this course. ACE provider approval period: 01/03/2020 – 01/03/2023.

To see other approvals in your state, see our state by state provider approval listings here.


Course Development: Each course is identified and reviewed by the appropriate Quantum Units Education consultant with professional and licensed expertise in the various disciplines we serve. Our professional consultants oversee course development to satisfy the needs of various professionals based on their board requirements, rate course degrees of difficulty and ensure the course content and exam questions are appropriate, relevant and comprehensive. See our professional staff and their bios here.

*Questions regarding how to take a course, refunds, grievance policy and ADA policy can be found here.
*Questions regarding this course or need support? Contact us at support@quantumunitsed.com.

Added On: 2018-09-17

Powered by LIFTOFF Digital | Web Design and Development